Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

New Trials

28 Apr 2008 08:09

Plant Health Care PLC28 April 2008 For immediate release 28 APRIL 2008 PLANT HEATH CARE PLC ("Plant Heath Care" or "the Company") Plant Health Care, Inc. initiates large scale grower tests for a ProActTM + Glyphosate product Plant Heath Care, (AIM: PHC.L), a leading provider of natural products forplants and soil, has initiated a large scale field trial program for corn,soybeans, and cotton to further evaluate the already established benefits ofusing ProActTM in combination with glyphosate, the world's most commonly usedherbicide, when applied over-the-top of glyphosate resistant crops. Five yearsof independent testing have demonstrated significant yield increases in cottonand corn when treated with a combination of ProAct and glyphosate. ProAct is afoliar spray product for reducing nematode populations and improving overallplant health. ProAct, which is the only foliar spray product labeled for useagainst nematodes in corn and soybeans, contains Harpin, a second generationharpin protein formulated as a wettable dry granule. PHC Director of Field Biology Ned French says, "ProAct increases yields. Thecomprehensive data from multi-year ProAct research shows average increases of2.5 bushels/acre in soybeans, 7 bushels/acre in corn, and 68 pounds of cottonlint/acre. These yield increases translate into economic returns of $28, $35,and $50/acre, respectively. The ProAct + Glyphosate Program will help bothgroups learn more about the benefits in real-world farming conditions." All participants will be asked to join a series of post-harvest teleconferencesto discuss how the ProAct + glyphosate tank-mix performed on their farms. PHCwill use the information gleaned from the teleconferences as the basis forbetter understanding farmer needs and perceptions as they relate to the use ofProAct + glyphosate. PHC, started in 1995, was originally focused on horticulture, turf, vegetablesand high value crops. The company started targeting field crops -corn, soybeans,and cotton - in 2007 based on its acquisition of harpin protein technologyproducts such as ProAct. ProAct contains the most recently developed andeffective generation of harpin proteins. Plant Health Care, Inc., headquartered in Pittsburgh, PA, is a wholly ownedsubsidiary of Plant Health Care plc (AIM:PHC), a leading provider of naturalproducts for plants and soil. PHC has operations in the United States, Mexico,the United Kingdom, Spain, and the Netherlands. PHC products are used in theagriculture, landscape, horticulture and land reclamation industries and areenvironmentally beneficial. Through the commercialization of these products, PHCis capitalizing on current long-term trends toward natural systems andbiological products for plant care and soil and water management. For moreinformation and complete details pertaining to the ProAct SatisfactionGuarantee, go to www.planthealthcare.com. -ends- For further information: Plant Heath Care plc John Brady, Chief Executive Tel: 001 603 525 3702 Evolution Securities Limited Tim Worlledge/ Tim Redfern Tel: 020 7071 4300 Tavistock Communications Jeremy Carey/Matt Ridsdale Tel: 020 7920 3150 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Apr 20227:00 amRNSHolding(s) in Company
19th Apr 20221:46 pmRNSNotice of results and investor presentation
11th Apr 202212:52 pmRNSHolding(s) in Company
1st Apr 20227:00 amRNSNew Distribution agreement with Ager Agro
14th Mar 202212:49 pmRNSHolding(s) in Company
11th Mar 202212:19 pmRNSHolding(s) in Company
3rd Feb 202212:56 pmRNSHolding(s) in Company
1st Feb 20221:16 pmEQSPlant Health Care, plc
1st Feb 20227:00 amRNS2021 Trading Statement
31st Jan 20227:00 amRNSPHC949 product registration submitted to the EPA
17th Jan 20227:00 amRNSInvestor Presentation
15th Dec 20217:00 amRNSWilbur Ellis and Plant Health Care discussion
13th Dec 20217:00 amRNSCommercial scale manufacturer for Saori
30th Nov 20214:36 pmRNSPrice Monitoring Extension
20th Oct 20216:03 pmRNSExercise of Options
22nd Sep 20217:00 amRNSNew agreement with Nutrien for Saori launch
22nd Sep 20217:00 amRNSInterim Report 30 June 2021
21st Sep 20214:41 pmRNSSecond Price Monitoring Extn
21st Sep 20214:35 pmRNSPrice Monitoring Extension
1st Sep 20217:00 amRNSArgentina approves Harpin as a seed treatment
24th Aug 20217:00 amRNSInvestor Presentation
18th Aug 20214:41 pmRNSSecond Price Monitoring Extn
18th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20211:27 pmRNSHolding(s) in Company
3rd Aug 20217:00 amRNSAdmission to the U.S. OTCQB Venture Market
27th Jul 20217:00 amRNSNew Distribution Agreement with Agrii UK
26th Jul 20217:00 amRNS2021 Half-Year Trading Statement
23rd Jul 20217:00 amRNSGrant of Options
22nd Jul 20217:00 amRNSInvestor Presentation
12th Jul 20214:40 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:35 pmRNSPrice Monitoring Extension
14th Jun 20212:33 pmRNSResult of AGM
14th Jun 20217:00 amRNSGreen Economy Mark awarded
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSInvestor Presentation
7th May 20213:50 pmRNSAnnual Report & Accounts and AGM Notice Published
30th Apr 20215:40 pmRNSHolding(s) in Company
23rd Apr 20217:00 amRNSResults for the year ended 31 December 2020
21st Apr 202111:58 amRNSHolding(s) in Company
8th Apr 20213:30 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSTotal Voting Rights
22nd Mar 20217:00 amRNSInvestor Presentation
18th Mar 20211:57 pmRNSResults of Placing and Subscription
18th Mar 20217:00 amRNSProposed Placing and Subscription
1st Mar 20217:00 amRNSSaori Trial Update
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.